Practice Guidelines in Oncology - Cedar Valley Breast Care Center
... HBOC CRITERIA g,h · Member of known BRCA1/BRCA2 kindred · Personal history of breast cancer + one or more of the following: ? Diagnosed age £ 40 yr, with or without family history ? Diagnosed age £ 50 yr or bilateral, with ³ 1 close blood relative with breast cancer or ³ 1 close blood relative with ...
... HBOC CRITERIA g,h · Member of known BRCA1/BRCA2 kindred · Personal history of breast cancer + one or more of the following: ? Diagnosed age £ 40 yr, with or without family history ? Diagnosed age £ 50 yr or bilateral, with ³ 1 close blood relative with breast cancer or ³ 1 close blood relative with ...
Recommendations on Prevention and Screening for Prostate Cancer
... Evidence from the Prostate, Lung, Colorectal and Ovary screening study (PLCO)32 and the ERSPC 33 are insufficient to support universal PSA screening to the general population, although ERSPC data with follow-up to 13 years showed continued improvement in risk reduction of prostate cancer mortality a ...
... Evidence from the Prostate, Lung, Colorectal and Ovary screening study (PLCO)32 and the ERSPC 33 are insufficient to support universal PSA screening to the general population, although ERSPC data with follow-up to 13 years showed continued improvement in risk reduction of prostate cancer mortality a ...
The dense breast
... and for soft – tissue lesions that are not seen or are poorly visualized on ultrasound particularly distortions ...
... and for soft – tissue lesions that are not seen or are poorly visualized on ultrasound particularly distortions ...
Hereditary predisposition to breast cancer – with a focus on AATF
... Around 5−10% of all breast cancer cases are estimated to result from a strong hereditary predisposition to the disease. However, mutations in the currently known breast cancer susceptibility genes account for only 20−30% of all familial cases. Additional factors contributing to the pathogenesis of b ...
... Around 5−10% of all breast cancer cases are estimated to result from a strong hereditary predisposition to the disease. However, mutations in the currently known breast cancer susceptibility genes account for only 20−30% of all familial cases. Additional factors contributing to the pathogenesis of b ...
2043-5531-1-SP
... Our recent study revealed very specific mutations in MED12 exon 2 in as many as 65% of uterine leiomyomas. We therefore hypothesised that these tumours might also harbor mutations in MED12. Uterine leiomyomas are benign smooth muscle tumors that can emanate from anywhere in the uterus and distort ut ...
... Our recent study revealed very specific mutations in MED12 exon 2 in as many as 65% of uterine leiomyomas. We therefore hypothesised that these tumours might also harbor mutations in MED12. Uterine leiomyomas are benign smooth muscle tumors that can emanate from anywhere in the uterus and distort ut ...
Target Ovarian Cancer: Position statement on family history
... ovarian and breast cancer in their family is thought to be missing some 40% of cases of inherited faulty BRCA genesiv. It is not clear why this is, but may be the case in families where there are not many female relatives. This is why a strategy to test all women with high grade serous ovarian cance ...
... ovarian and breast cancer in their family is thought to be missing some 40% of cases of inherited faulty BRCA genesiv. It is not clear why this is, but may be the case in families where there are not many female relatives. This is why a strategy to test all women with high grade serous ovarian cance ...
CONCLUSION: Bilateral breast cancer is uncommon and
... ABSTRACT: This is a report of a case of carcinoma of breast occurring simultaneously in both breasts in a middle aged woman who presented initially with a mass in the left breast. On clinical and radiological examination a mass lesion was also identified in the contralateral breast. Histopathology r ...
... ABSTRACT: This is a report of a case of carcinoma of breast occurring simultaneously in both breasts in a middle aged woman who presented initially with a mass in the left breast. On clinical and radiological examination a mass lesion was also identified in the contralateral breast. Histopathology r ...
KRAS, EGFR AND PIK3CA mutation in triple negative breast
... (TNBC) constitutes 10-17 % of all breast cancers. These tumors are mostly observed in women with BRCA1/2 mutation carriers at a younger age (<50 years), and are resistant to the chemotherapy used, have more aggressive clinical course and poor prognosis (2). Genomic studies carried out in TNBCs aim t ...
... (TNBC) constitutes 10-17 % of all breast cancers. These tumors are mostly observed in women with BRCA1/2 mutation carriers at a younger age (<50 years), and are resistant to the chemotherapy used, have more aggressive clinical course and poor prognosis (2). Genomic studies carried out in TNBCs aim t ...
TP53 and Ovarian Cancer
... most important determinant of clinical outcome is the surgicopathologic stage at the initial time of diagnosis. The staging system defined by the International Federation of Gynecologic Oncologists [FIGO, 1971; Cannistra, 1993]. For patients with stage I disease survival rates have been reported ove ...
... most important determinant of clinical outcome is the surgicopathologic stage at the initial time of diagnosis. The staging system defined by the International Federation of Gynecologic Oncologists [FIGO, 1971; Cannistra, 1993]. For patients with stage I disease survival rates have been reported ove ...
October is Breast Cancer Awareness Month.
... had raised more than $660 million worldwide. The Avon Breast Cancer Crusade launched in 1992 and has raised more than $585 million in more than fifty countries, making Avon the leading corporate supporter of the breast cancer cause. Breast cancer is the most commonly diagnosed cancer among women, an ...
... had raised more than $660 million worldwide. The Avon Breast Cancer Crusade launched in 1992 and has raised more than $585 million in more than fifty countries, making Avon the leading corporate supporter of the breast cancer cause. Breast cancer is the most commonly diagnosed cancer among women, an ...
ATM Mutations in Cancer - Molecular Cancer Therapeutics
... ATM germ-line mutations (25). However, this association has been subject to some controversy. A study of young patients with breast cancer (and no known family history of A-T syndrome) detected heterozygous truncating ATM mutations in only 0.5% of cases, less than the rate predicted by the preceding ...
... ATM germ-line mutations (25). However, this association has been subject to some controversy. A study of young patients with breast cancer (and no known family history of A-T syndrome) detected heterozygous truncating ATM mutations in only 0.5% of cases, less than the rate predicted by the preceding ...
BRCA2
BRCA2 and BRCA2 (/ˌbrækəˈtuː/) are a human gene and its protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (breast cancer 2, early onset) are maintained by the HGNC. Orthologs, styled Brca2 and Brca2, are common in other mammal species. BRCA2 is a human tumor suppressor gene (specifically, a caretaker gene), found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer. Thus, although the terms ""breast cancer susceptibility gene"" and ""breast cancer susceptibility protein"" (used frequently both in and outside the medical literature) sound as if they describe a proto-oncogene or oncogene, BRCA1 and BRCA2 are ""normal""; it is their mutation that is abnormal.The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3). The human reference BRCA 2 gene contains 28 exons, and the cDNA has 10,254 base pairs coding for a protein of 3418 amino acids.The gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the University of Pennsylvania.Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.